(R)-(+)-2-甲氧基丙酸 | 23943-96-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-(+)-2-甲氧基丙酸
• 中文别名: 2-甲氧基丙酸；R-2-甲氧基丙酸
• 英文名称: (R)-2-methoxypropanoic acid
• 英文别名: (R)-(+)-2-methoxypropionic acid；(2R)-2-methoxypropanoic acid；(R)-2-methoxypropanic acid
• CAS: 23943-96-6
• 化学式: C₄H₈O₃
• 分子量: 104.106
• InChiKey: ICPWFHKNYYRBSZ-GSVOUGTGSA-N

物化性质

• 沸点：
  108-110°C/30 mm
• 密度：
  1.1141 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、乙酸乙酯（少许）、甲醇（少许）
• 稳定性/保质期：
  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918990090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  存放在阴凉干燥处即可。

SDS

Name:	(R)-(-)-2-Methoxypropionic acid Material Safety Data Sheet
Synonym:
CAS:	23943-96-6

Section 1 - Chemical Product MSDS Name:(R)-(-)-2-Methoxypropionic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
23943-96-6	(R)-(-)-2-Methoxypropionic acid		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 23943-96-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Clear slightly yellow liquid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: > 110 deg C (> 230.00 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: CH3CH(OCH3)COOH
Molecular Weight: 104.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 23943-96-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(R)-(-)-2-Methoxypropionic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 23943-96-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 23943-96-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 23943-96-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-(+)-2-甲氧基丙酸 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 生成 R-(+)-2-methoxypropionic acid chloride
  参考文献：
  名称：

  N-甲基咪唑介导的外消旋仲醇在旋光酰氯存在下的动力学拆分

  摘要：

  N-甲基咪唑用于促进仲外消旋醇的酰化，并通过中间体手性酰基咪唑氯化物进行动力学拆分。在催化量的N-甲基咪唑存在下，动力学拆分可以转化为催化过程。

  DOI：

  10.1002/ejoc.200901075
• 作为产物：
  描述：

  methyl (2R)-2-methoxypropanoate 在 甲醇 、 1,2,3,5,6,7-六氢-S-并二苯 、 水 作用下， 以 四氢呋喃 为溶剂， 以82%的产率得到(R)-(+)-2-甲氧基丙酸
  参考文献：
  名称：

  从机会性病原体堪萨斯分枝杆菌中合成十三糖脂寡糖抗原

  摘要：

  合成了来自机会性病原体堪萨斯分枝杆菌的脂寡糖的十三糖聚糖结构域。目标（见结构）具有使其合成成为一项艰巨挑战的结构基序，包括稀有单糖、不对称取代的海藻糖残基和对碱敏感的酰胺侧链。该研究为合成这一类不寻常分子的其他成员提供了一种策略。

  DOI：

  10.1002/anie.202111549

文献信息

• INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION
  申请人：Charron Catherine Elisabeth

  公开号：US20120244120A1

  公开（公告）日：2012-09-27

  The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

  本发明涉及治疗或预防流感病毒感染（包括亚型流感A病毒、流感B病毒、禽流感H5N1、A/H1N1、H3N2和/或大流行性流感）的化合物，这些化合物抑制p59-HCK的活性，并涉及一种筛选候选药物物质的方法，该方法旨在预防或治疗受试者的流感病毒感染，所述方法包括识别能够抑制p59-HCK活性的试验物质。
• [EN] (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL) UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT<br/>[FR] DÉRIVÉS DE (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TÉTRAHYDRONAPHTALÉN-1-YL)URÉIDO EN TANT QU'INHIBITEURS DE P38 MAPK ANTI-INFLAMMATOIRES POUR TRAITER DES MALADIES DU TRACTUS RESPIRATOIRE
  申请人：CHIESI FARM SPA

  公开号：WO2018224423A1

  公开（公告）日：2018-12-13

  This invention relates to (4-(([l,2,4]triazolo[4,3-a]pyridine-6-yl) oxy)-1,2,3,4-tetrahydronaphthalen-1-yl)ureido derivatives that are p38 MAPK (mitogen activated protein kinase) inhibitors as antiinflammatory agents for treating diseases of the respiratory tract.

  本发明涉及(4-(([1,2,4]三唑[4,3-a]吡啶-6-基)氧基)-1,2,3,4-四氢萘-1-基)脲衍生物，该衍生物作为抗炎剂用于治疗呼吸道的疾病，是p38 MAPK（丝裂原活化蛋白激酶）的抑制剂。
• Synthesis of Carbapenems Containing Peptidoglycan Mimetics and Inhibition of the Cross‐Linking Activity of a Transpeptidase of <scp>l,d</scp> Specificity
  作者：Saidbakhrom Saidjalolov、Zainab Edoo、Matthieu Fonvielle、Louis Mayer、Laura Iannazzo、Michel Arthur、Mélanie Etheve‐Quelquejeu、Emmanuelle Braud

  DOI：10.1002/chem.202004831

  日期：2021.2.15

  The carbapenem class of β‐lactams has been optimized against Gram‐negative bacteria producing extended‐spectrum β‐lactamases by introducing substituents at position C2. Carbapenems are currently investigated for the treatment of tuberculosis as these drugs are potent covalent inhibitors of l,d‐transpeptidases involved in mycobacterial cell wall assembly. The optimization of carbapenems for inactivation

  碳青霉烯类β-内酰胺类通过针对C2位置引入取代基而针对产生广谱β-内酰胺酶的革兰氏阴性细菌进行了优化。目前正在研究碳青霉烯类药物用于治疗结核病，因为这些药物是l，d的有效共价抑制剂参与分枝杆菌细胞壁组装的转肽酶。本文通过利用C 8羟基的亲核性引入化学多样性来寻找用于灭活这些异常靶标的碳青霉烯类的优化。由于β-内酰胺是肽聚糖前体的结构类似物，因此选择取代基可增加药物和底物之间的相似性。有效地合成了十四个肽-卡宾。由于在位置C2引入苯乙硫基取代基的积极影响，它们比美罗培南参考药物更有效，但在位置C8添加的拟肽不能进一步提高活性。因此，可以修饰位置C8以调节高效碳青霉烯类的药代动力学性质。
• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2021168038A1

  公开（公告）日：2021-08-26

  The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

  本公开提供了用于治疗各种疾病的化合物，如呼吸道合胞病毒（RSV）、HRV、hMPV、埃博拉、寨卡、西尼罗河病毒、登革热和丙型肝炎病毒。